・サブグループ解析1 本論文では、MITRA-FRのグループをCOAPT criteriaで層別化してTable1の集団特性がCOAPTに近いことを確認して解析し直しましたが予後改善効果はやはり得られませんでした。 https://t.co/QYk61Clktj 7/n
RT @nishiki8885: COAPTとMitra-FRで一年後のGDMT内容が違うっていう論文をなんのやつかメモできなかったんですがどなたかご存知ないですか?? #GDMT #22JCS
RT @nishiki8885: COAPTとMitra-FRで一年後のGDMT内容が違うっていう論文をなんのやつかメモできなかったんですがどなたかご存知ないですか?? #GDMT #22JCS
RT @nishiki8885: by 日循サポーター #22JCS @JCIRC_IPR
RT @nishiki8885: Debate 6 severe FMRに対してClip first? GDMT first? 大阪大学 坂田先生 Mitra-FR vs COAPT から何を学ぶか? ✔︎ 患者選択 Disproportionateだけでは説明がつかない。 h…
by 日循サポーター #22JCS @JCIRC_IPR
Debate 6 severe FMRに対してClip first? GDMT first? 大阪大学 坂田先生 Mitra-FR vs COAPT から何を学ぶか? ✔︎ 患者選択 Disproportionateだけでは説明がつかない。 https://t.co/XioXzUSgwY ✔︎ GDMTの質 COAPT数ヶ月かけて実施± CRT MITRA-FR各医師の裁量 Baseline→1年後のGDMT内容が違う❗️
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @KagiyamaNobu: 土曜のEcho NYで印象的だったのはDr SaranoもDr Delgadoもproportionate / disproportionate MRの概念に否定的だったというところですね。 下記の二つの論文は前も紹介したけど重要 http…
RT @KagiyamaNobu: 土曜のEcho NYで印象的だったのはDr SaranoもDr Delgadoもproportionate / disproportionate MRの概念に否定的だったというところですね。 下記の二つの論文は前も紹介したけど重要 http…
RT @KagiyamaNobu: 土曜のEcho NYで印象的だったのはDr SaranoもDr Delgadoもproportionate / disproportionate MRの概念に否定的だったというところですね。 下記の二つの論文は前も紹介したけど重要 http…
結局は、手技の質の問題な気がしています
RT @KagiyamaNobu: 土曜のEcho NYで印象的だったのはDr SaranoもDr Delgadoもproportionate / disproportionate MRの概念に否定的だったというところですね。 下記の二つの論文は前も紹介したけど重要 http…
やはりこの概念は否定的な流れなんですね。
RT @KagiyamaNobu: 土曜のEcho NYで印象的だったのはDr SaranoもDr Delgadoもproportionate / disproportionate MRの概念に否定的だったというところですね。 下記の二つの論文は前も紹介したけど重要 http…
土曜のEcho NYで印象的だったのはDr SaranoもDr Delgadoもproportionate / disproportionate MRの概念に否定的だったというところですね。 下記の二つの論文は前も紹介したけど重要 https://t.co/yF5FWbGwGj https://t.co/iShHQOGnBg https://t.co/pBgqkLVYP4
RT @Susumu_Manabe: Mitra clipに適した病態とは?二次性僧帽弁閉鎖不全症の中でも、左室機能低下に比して相対的に僧帽弁逆流が大きい症例がよい、 という考えが一般的であるが、それに一石を投じる報告。どんな患者群でも明らかなmitraclip の優位性は認め…
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @DrMoritzWvB: The ‘disproportionate MR’ theory proposed to explain conflicting findings of the #TEER benefit in #FMR patients has not wo…
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @EGarciaSayan: No subset of patients (including those w ERO/EDV ≥ 0.15) that may have benefited from TEER could be identified in further…
No subset of patients (including those w ERO/EDV ≥ 0.15) that may have benefited from TEER could be identified in further analysis of MITRA-FR results. Should we look beyond proportionate/disproportionate for COAPT-like pts? Severity of illness, RV functio
RT @DrMoritzWvB: The ‘disproportionate MR’ theory proposed to explain conflicting findings of the #TEER benefit in #FMR patients has not wo…
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @DrMoritzWvB: The ‘disproportionate MR’ theory proposed to explain conflicting findings of the #TEER benefit in #FMR patients has not wo…
RT @DrMoritzWvB: The ‘disproportionate MR’ theory proposed to explain conflicting findings of the #TEER benefit in #FMR patients has not wo…
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @DrMoritzWvB: The ‘disproportionate MR’ theory proposed to explain conflicting findings of the #TEER benefit in #FMR patients has not wo…
RT @DrMoritzWvB: The ‘disproportionate MR’ theory proposed to explain conflicting findings of the #TEER benefit in #FMR patients has not wo…
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @DrMoritzWvB: The ‘disproportionate MR’ theory proposed to explain conflicting findings of the #TEER benefit in #FMR patients has not wo…
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @DrMoritzWvB: The ‘disproportionate MR’ theory proposed to explain conflicting findings of the #TEER benefit in #FMR patients has not wo…
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @DrMoritzWvB: The ‘disproportionate MR’ theory proposed to explain conflicting findings of the #TEER benefit in #FMR patients has not wo…
RT @DrMoritzWvB: The ‘disproportionate MR’ theory proposed to explain conflicting findings of the #TEER benefit in #FMR patients has not wo…
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @DrMoritzWvB: The ‘disproportionate MR’ theory proposed to explain conflicting findings of the #TEER benefit in #FMR patients has not wo…
RT @DrMoritzWvB: The ‘disproportionate MR’ theory proposed to explain conflicting findings of the #TEER benefit in #FMR patients has not wo…
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @DrMoritzWvB: The ‘disproportionate MR’ theory proposed to explain conflicting findings of the #TEER benefit in #FMR patients has not wo…
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @JACCJournals: Exploring the MITRA-FR trial: Can #echofirst parameters explain conflicting results with the #COAPT trial? Find out in th…
RT @gbiondizoccai: "In MITRA-FR, we could not identify a subset of patients, including those deemed as having disproportionate MR, that mig…
"In MITRA-FR, we could not identify a subset of patients, including those deemed as having disproportionate MR, that might have benefited from transcatheter correction using MitraClip" https://t.co/rBlm9jMzGk https://t.co/KDmVnkt48H
Just out @JACCJournals #JACCImg MITRA-FR: MR severity, LV remodeling or combination no benefit even in disproportionate SMR. Thoughts? @GreggWStone @hahn_rt @vonBardelebenRS @modine_thomas @m_taramasso @azeemlatib @JamesDThomasMD1 https://t.co/vc4kadBcEV
RT of @MalergueMarie ☀️☀️
Proportionalityのの話題とかまだ生き残っているのだろうか...
事態は結構混沌としてて ・COAPTの他のsubstudyではどのようなsubgroupでもClipは効く ・MITRA-FRの別のsubstudyではどのsubgroupにもClipは効かない ちゃんとデータの全詳細を眺めてみる必要がありますが、いずれにしてもRESHAPE2待ちか、、、 https://t.co/KhN2rSxRgu https://t.co/noWW6SNbUP
@echo_stepbystep @iamritu @LindaGillamMD @purviparwani @NadeenFaza @gb_mackensen @SLittleMD @AkhilNarangMD @tiffchenMD @OKhaliqueMD @LucySafi @DrDeepa1020 Also note recent @JACCJournals post-hoc analysis of MITRA-FR 🔺Puts proportionate-disproportionate c
RT @DonalErwan: Let’s continue to research ! Impact of Mitral Regurgitation Severity and Left Ventricular Remodeling on Outcome After Mitra…
Let’s continue to research ! Impact of Mitral Regurgitation Severity and Left Ventricular Remodeling on Outcome After Mitraclip Implantation https://t.co/9fvIqqmB4k @Cosyns @EACVIPresident @AugustinCoisne @PezelT
RT @argulian: In post hoc analysis of MITRA-FR, none of subgroups defined based on EROA, LV size or both derived benefit from intervention.…
他のトライアル見ても重症度のスクリーニングフェイラーが多いようなので今後はMRでの評価も考えた方が良いのでは?Impact of Mitral Regurgitation Severity and Left Ventricular Remodeling on Outcome After Mitraclip Implantation https://t.co/Vqu1lY2HYZ
RT @DonalErwan: Impact of Mitral Regurgitation Severity and Left Ventricular Remodeling on Outcome After Mitraclip Implantation https://t.c…
RT @argulian: In post hoc analysis of MITRA-FR, none of subgroups defined based on EROA, LV size or both derived benefit from intervention.…
RT @argulian: In post hoc analysis of MITRA-FR, none of subgroups defined based on EROA, LV size or both derived benefit from intervention.…
RT @argulian: In post hoc analysis of MITRA-FR, none of subgroups defined based on EROA, LV size or both derived benefit from intervention.…
RT @argulian: In post hoc analysis of MITRA-FR, none of subgroups defined based on EROA, LV size or both derived benefit from intervention.…
In post hoc analysis of MITRA-FR, none of subgroups defined based on EROA, LV size or both derived benefit from intervention. This is inconsistent with 'proportionality' hypothesis. Debate continues! https://t.co/A6dQdzHZBt https://t.co/kmKlzZzxtA
RT @Susumu_Manabe: Mitra clipに適した病態とは?二次性僧帽弁閉鎖不全症の中でも、左室機能低下に比して相対的に僧帽弁逆流が大きい症例がよい、 という考えが一般的であるが、それに一石を投じる報告。どんな患者群でも明らかなmitraclip の優位性は認め…
RT @Susumu_Manabe: Mitra clipに適した病態とは?二次性僧帽弁閉鎖不全症の中でも、左室機能低下に比して相対的に僧帽弁逆流が大きい症例がよい、 という考えが一般的であるが、それに一石を投じる報告。どんな患者群でも明らかなmitraclip の優位性は認め…
News about the #proportionality concept of #MR in #Mitrafr patients #TMVR #Mitralvalve #heartfailure https://t.co/uTlfHEYfYJ
RT @DonalErwan: Impact of Mitral Regurgitation Severity and Left Ventricular Remodeling on Outcome After Mitraclip Implantation https://t.c…
RT @DonalErwan: Impact of Mitral Regurgitation Severity and Left Ventricular Remodeling on Outcome After Mitraclip Implantation https://t.c…
RT @DonalErwan: Impact of Mitral Regurgitation Severity and Left Ventricular Remodeling on Outcome After Mitraclip Implantation https://t.c…
RT @Susumu_Manabe: Mitra clipに適した病態とは?二次性僧帽弁閉鎖不全症の中でも、左室機能低下に比して相対的に僧帽弁逆流が大きい症例がよい、 という考えが一般的であるが、それに一石を投じる報告。どんな患者群でも明らかなmitraclip の優位性は認め…
RT @Susumu_Manabe: Mitra clipに適した病態とは?二次性僧帽弁閉鎖不全症の中でも、左室機能低下に比して相対的に僧帽弁逆流が大きい症例がよい、 という考えが一般的であるが、それに一石を投じる報告。どんな患者群でも明らかなmitraclip の優位性は認め…
RT @KagiyamaNobu: これめっちゃ大事で、Mitra-FRとCOAPTの違いは世間で言われるようなdisproportions とかいう概念だけでは説明がつかないんじゃないだろうかというのが肌感としてもある。 本来、患者背景に更に注目したRCTの追試が必要なとこ…
Excellent Erwan. The names of the contributors speak for themselves, regarding their experience and deep knowledge of the topic!
RT @DonalErwan: Impact of Mitral Regurgitation Severity and Left Ventricular Remodeling on Outcome After Mitraclip Implantation https://t.c…
RT @DonalErwan: Impact of Mitral Regurgitation Severity and Left Ventricular Remodeling on Outcome After Mitraclip Implantation https://t.c…
Impact of Mitral Regurgitation Severity and Left Ventricular Remodeling on Outcome After Mitraclip Implantation https://t.co/tKIpxtwV3V @EchoFiliale @AugustinCoisne @Cosyns @k_yiangou
RT @surface4user: 数年前からクリップそんなに良いか?と疑問がどんどんでてきてて、これ。 三尖弁クリップも同様で、慢性TR 右室不全を急に置換して右室不全を悪化させると、術後全然立ち上がらなかったりRvadから離脱できない症例がいる。 うちは1ヶ月で一人死亡も…